The International Council for Harmonisation (ICH) released a widely anticipated timetable detailing its plans to issue general guidance on model-informed drug development (MIDD) approaches in drug ...

Details on the US Food and Drug Administration’s (FDA) plans for launching a pilot project on model-informed drug development (MIDD) began trickling out on Monday with a Federal Register notice.

Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...

More than 1,400 participants across 65+ countries underscores accelerating adoption of model-informed workflows and growing demand for applied modeling expertise Simulations Plus, Inc. (Nasdaq: SLP) ( ...

Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and ...

The recent reductions in the US Food and Drug Administration’s workforce are poised to have a substantial impact on drug and biologic development programs. This LawFlash discusses strategies to ...

The global In Silico Clinical Trials market offers significant opportunities due to the growing demand for faster drug ...

Altasciences and Certara ink strategic partnership to accelerate early drug development: Laval, Quebec Saturday, May 9, 2026, 15:00 Hrs [IST] Altasciences, a fully integrated drug ...

LAVAL, Québec & RADNOR, Pa.--(BUSINESS WIRE)--#Altasciences--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug ...